Sign up USA
Proactive Investors - Run By Investors For Investors

Allergan accused of taking advantage of tribal sovereignty in patent dispute with Mylan

Allergan has transferred several patents relating to Restasis to the Native American St. Regis Mohawk Tribe
eye drops
Allergan is locked in a legal dispute with Mylan over its dry eye treatment

Drugmaker Allergan PLC (NYSE:AGN) has been taking advantage of Native American sovereignty to protect its patent for dry-eye treatment Restasis, rival Mylan Inc (NYSE:MYL) has alleged in a court filing.

Allergan on Friday said it had reached a deal to transfer several patents relating to Restasis to the Native American St. Regis Mohawk Tribe.

READ: Allergan shares move lower as second quarter losses almost double year-on-year

Mylan said in Federal District Court in Marshall, Texas, that Allergan was “attempting to misuse Native American sovereignty to shield invalid patents from cancellation”.

Allegan claims the tribe’s status as a sovereign nation means the patents for the drug would no longer be subject to review by the US Patent Trial and Appeal Board.

Generic drug companies often challenge patents before the board.

However, Allergan is not the only company to use the Regis Mohawk Tribe to shield its patents.

According to US Patent and Trademark Office records, SRC Labs LLC transferred around 40 patents to the tribe on 2 August, suggesting that such a tactic could be used by companies beyond the pharmaceutical sector.

Shares in Allergan edged down 0.48% to US$230.26 in afternoon trading.

View full AGN profile View Profile

Allergan Timeline

Related Articles

1507647205_biotech_517925923.jpg
October 10 2017
Last month the group revealed its Barocycler 2320EXTREME device had been selected as a finalist in the prestigious R&D 100 Awards for 2017.
couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use